Participants were willing to pay an additional AU$862 for the narrow-spectrum option, reflecting a significant preference despite price influences.
p-value: p=<0.001
While narrow-spectrum antimicrobials are preferred for targeted therapy by health practitioners with AMS expertise, price significantly influenced drug choice. Willingness-to-pay values reflect the knowledge and experience of AMS experts who are best-placed to gauge the opportunity costs of paying more for narrow-spectrum antimicrobials. These findings can inform the quantification of spectrum-value for health-system funding decisions.
Paradiso et al. (Wed,) conducted a other in Narrow-spectrum antimicrobials (n=155). Narrow-spectrum antimicrobial vs. Broad-spectrum antimicrobial was evaluated on Willingness to pay for a narrow-spectrum option (95% CI 726-998, p=<0.001). Participants were willing to pay an additional AU$862 for the narrow-spectrum option, reflecting a significant preference despite price influences.